Background. Immediate reversal of anticoagulation is essential when facing severe bleeding or emergency surgery. Although idarucizumab is approved for the reversal of dabigatran in many countries, clinical experiences are lacking, particularly in special patient-populations such as sepsis and impaired renal function. Case Presentation. We present the case of a 67-year-old male septic patient with a multilocular facial abscess and chronic kidney disease (GFR 36.5 mL/min). Thrombin time (TT) and activated partial thromboplastin time (aPTT) 15 hours after the last intake of 150 mg dabigatran were both prolonged (>120 sec, resp., 61 sec), as well as unbound dabigatran concentration (119.05 ng/mL). Before immediate emergency surgery dabigatran was antagonised using idarucizumab 2 × 2.5 g. Dabigatran concentration was not detectable 10 min after idarucizumab administration (<30 ng/mL). TT and aPTT time were normalised (16.2 sec, resp., 30.2 sec). Sepsis was controlled after surgery and kidney function remained stable. In the absence of postoperative bleeding, dabigatran was restarted 36 hours after admission. Conclusion. Idarucizumab successfully reversed the effect of dabigatran in real-life practice in a patient with sepsis and renal impairment and allowed emergency surgery with normal haemostasis. Efficacy and safety in real-life practice will nevertheless require prospective registries monitoring.
The 67-year-old male patient was admitted to our emergency department because of swelling in his right cheek since the previous day. He had a history of atrial fibrillation, which had been treated with dabigatran, 150 mg twice daily (last dose 15-16 hours before presentation), and suffered from chronic renal impairment due to type II diabetes mellitus and hypertension. The febrile patient was haemodynamically stable on admission. The physical examination revealed significant hot and painful right facial swelling. The laboratory results on admission were as follows: white blood count 17.7 Giga/L; C-reactive protein 234 mg/L; creatinine 165 μmol/L (GFR 36.5 mL/min); and unbound dabigatran concentration as measured with diluted thrombin time (dTT; Hyphen Hemoclot, Neuville-sur-Oise, France) 119.05 ng/mL. The activated partial thromboplastin time (aPTT) and thrombin time were prolonged (61 sec, resp., <120 sec). For a summary of coagulation tests, see Table 1. We administered 2.2 g i.v. Co-Amoxicillin and computed tomography was performed to plan abscess surgery.
Coagulation tests.
Parameter
Standard values
Before idarucizumab
10 minutes after 2×2.5 g idarucizumab
24 hours after idarucizumab
INR
1.56
1.23
1.10
aPTT (sec)
25.0–36.0
61
30.2
41.5
Thrombin time (sec)
11.5–19.4
>120
16.2
52.9
Fibrinogen (g/L)
1.75–3.75
7.11
7.11
7.09
Dabigatran (ng/mL)
119.05
<30.0
<30.0
Activated partial thromboplastin time (aPTT); international normalised ratio (INR).
As the patient was becoming increasingly septic and haemodynamically unstable despite volume substitution, emergency surgery was indicated.
We administered a 2.5 g infusion of idarucizumab, followed by a second infusion of 2.5 g idarucizumab after 10 minutes. No side effects were reported by the patient.
Immediately after the second dose, coagulation testing was repeated and aPTT as well as thrombin time were found to be normal; dabigatran concentration was below detection limit (<30 ng/mL; see Table 1). Thirty minutes after idarucizumab application, enoral incision of the multilocular abscess was performed, with irrigation and insertion of Penrose and Easy Flow drainage. There was no relevant blood loss and no other complications. The surgical team rated the intraoperative bleeding as being “as expected.”
The patient could be managed postoperatively on an ordinary surgical ward with rapid clinical improvement. Coagulation tests were repeated 24 hours after administration of idarucizumab (Table 1). Postoperative kidney function improved after treatment of infection (creatinine 115 μmol/L, GFR 56 mL/min, day 6). As there was no postoperative bleeding, dabigatran was restarted 36 hours after surgery and administration of idarucizumab. The patient was discharged from hospital without any complications.
3. Discussion
We report the successful administration of idarucizumab to a septic patient with chronic kidney disease, in order to facilitate emergency surgery for facial abscess.
Although our patient presented about 15-16 hours after the last 150 mg dose of dabigatran, coagulation tests were still markedly prolonged and a relevant dabigatran concentration was present. Given the patient’s rapid clinical deterioration and his impaired renal function, we decided to administer the antidote, rather than waiting for the dabigatran to be cleared. As only 13 patients in the RE-VERSE AD study (33%) had creatinine clearance <50 mL/min, experience with application of idarucizumab and restarting of dabigatran in patients with impaired renal function is limited [5].
The RE-VERSE AD trail included two patients with abscesses only, in the suprapubic and scrotal locations [5]. However, bleeding in abscess surgery can be critical, particularly in oral surgery where haemorrhages may compromise the airway and lead to aspiration that requires invasive airway management. In our patient, reversal of anticoagulation led to immediate normalisation of all coagulation tests. Normal intraoperative haemostasis, as reported by the surgical team in our case, is consistent with the 92% of patients in the RE-VERSE AD trail [5].
Twenty-four hours after surgery and administration of idarucizumab, we found that aPTT and thrombin time were mildly prolonged again. Most probably, these changes are caused by redistribution of unbound dabigatran not detected by the diluted thrombin time. Even in patients with severe renal impairment idarucizumab is most likely to be cleared at 24 h hours and therefore cannot bind redistributed dabigatran anymore. It has been previously reported that even very low doses of 25 ng/mL dabigatran (below the detection limit of our test, <30 ng/mL) may lead to immeasurably high thrombin times [6]. This prolongation in the coagulation tests did not lead to any clinical bleeding in our patient but may cause confusion. It is important to point out that the aPTT is likely to be prolonged in the presence of dabigatran, but the degree of prolongation does not correlate well with the level of anticoagulant activity.
In-hospital acute kidney injury is common, especially in patients with sepsis (2–18% of all hospital inpatients) and needs close monitoring of renal function to determine whether and at which dosage therapy with dabigatran can be continued [7, 8]. In our patient, the kidney function improved after treatment of infection and he could be discharged with dabigatran into the care of his general practitioner for close monitoring.
4. Conclusion
Idarucizumab reversed the effect of dabigatran treatment successfully in real-life practice in a patient with sepsis and renal impairment and allowed emergency surgery with normal haemostasis. As there is limited experience with idarucizumab efficacy and safety in real-life practice shall be monitored in prospective registries.
Consent
Written patient consent for publication was obtained.
Competing Interests
The authors have no competing interests.
ProvidênciaR.GroveE. L.HustedS.BarraS.BovedaS.MoraisJ.A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens201413461253126410.1016/j.thromres.2014.10.0022-s2.0-84915793225SauterT. C.AmylidiA.-L.RicklinM. E.LehmannB.ExadaktylosA. K.Direct new oral anticoagulants in the emergency department: experience in everyday clinical practice at a Swiss university hospital201629e13e1510.1016/j.ejim.2015.12.0092-s2.0-84952903669Fenger-EriksenC.MünsterA.-M.GroveE. L.New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications201458665165910.1111/aas.123192-s2.0-84903135364KalusJ. S.Pharmacologic interventions for reversing the effects of oral anticoagulants20137010, supplement 1S12S21PollackC. V.ReillyP. A.EikelboomJ.GlundS.VerhammeP.BernsteinR. A.DubielR.HuismanM. V.HylekE. M.KamphuisenP. W.KreuzerJ.LevyJ. H.SellkeF. W.StangierJ.SteinerT.WangB.KamC.-W.WeitzJ. I.Idarucizumab for dabigatran reversal2015373651152010.1056/nejmoa15020002-s2.0-84938836381CukerA.SiegalD. M.CrowtherM. A.GarciaD. A.Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants201464111128113910.1016/j.jacc.2014.05.0652-s2.0-84922394366LewingtonA. J. P.CerdáJ.MehtaR. L.Raising awareness of acute kidney injury: a global perspective of a silent killer201384345746710.1038/ki.2013.1532-s2.0-84883449882BellomoR.KellumJ. A.RoncoC.Acute kidney injury2012380984375676610.1016/s0140-6736(11)61454-22-s2.0-84865389203